Looking back on Iconovo’s 2019, the company’s investment in the new inhalation platform ICOpre and the accompanying dry power formulations stands out.

This new project will enable the company to offer global generics for GSK’s Ellipta range, a range that is expected to reach a market value of 5 billion USD the year before the patent expires in 2025. Strengthened by 60 MSEK in institutional capital, Iconovo is now pushing ahead on several fronts. Read more